By IDSE News Staff
The recently approved fecal microbiota, live-jslm (Rebyota, Ferring) is now available in the United States, the company announced.
Fecal microbiota, live-jslm was approved by the FDA on Nov. 30, 2022, to prevent recurrence of Clostridioides difficile infection (CDI) in people 18 years of age and older, following antibiotic treatment for recurrent CDI.
Fecal microbiota, live-jslm is a pre-packaged, single-dose 150-mL microbiota suspension for rectal administration